In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Amgen invests $25mm in Infinity with drug development deal

Executive Summary

Infinity Pharmaceuticals (focuses on developing cancer therapeutics) licensed Amgen nonexclusive rights to its collection of small molecules, which it will use to identify potential therapeutic agents over a three-year period. In return, Amgen made a $25mm investment in the company for less than a 15% stake.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
      • Molecular Diversity
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Contract
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register